All three models agree that LLY is poised for a 1-3 week swing toward $1220-$1250, driven by the September 18 FDA approval of the Inluriyo+Verzenio combo and Mounjaro’s label expansion. Technicals show a bounce off the $1161-$1165 support shelf with rising RSI and a bullish MACD zero-cross, supported by sector tailwinds in XLV and TLT. One model specifically highlights a 3-0 winning record for prior support retests and an analyst EPS estimate lift as additional catalysts for the move past the $1186 resistance barrier.
All three models identify a high-probability mean-reversion short as LLY hits the 4h upper Bollinger Band near the $1186 resistance shelf on exhausted volume (4th percentile). They argue the FDA catalysts are already priced in, creating a 'fade-the-extension' setup as 30m momentum declines and the stock faces structural headwinds from MFN drug-pricing policies. The models target a pullback toward the $1153 value-area midpoint or as low as $1125 if the current push fails to attract fresh participation.
- →A close below $1140 on the 4-hour timeframe would invalidate this thesis, signaling a breakdown from key support and a potential shift in trend participation.
Individual Model Analysis
Bull/Bear Competition · case scoresWinner: BULL
Case scores describe the displayed analysis. Average confidence combines this model’s majority runs.
LLY is holding just above 1day support ( $1165.81) with a fresh Sep 18 FDA full approval for the Inluriyo+Verzenio breast-cancer combo plus a recent Mounjaro cardiovascular label expansion, both broadening the addressable oncology and car dio metabolic markets. Momentum is turning up (4h RSI 58 rising, MACD histogram positive/rising, daily bullish zero-cross) inside a calm/bullish regime, with XLV and TLT both confirming the move. The expected path is a push from the $1165 support shelf toward the $1186 resistance band over the 1-3 week swing as the catalyst and improving momentum draw participation.
LLY is 9.6% below its 52-week high and rejected repeatedly near the $1186 resistance shelf, where prior long trades stalled; a short works only if price rallies into that supply zone and fails again amid depressed volume and a stretched 4h tape trading above its upper Bollinger band. The tactical case is fade-the-extension: rising RSI into overbought territory on the 30m/4h with volume z-score of -1.17 argues the current push lacks participation, so a retest of $1186 offers an asymmetric fade back toward the POC/value-area midpoint near $1153. Overhead MFN drug-pricing policy headwind (3.9% reduction theme) provides a slow structural fundamental drag for the broader portfolio.
Bull/Bear Competition · case scoresWinner: BULL
Case scores describe the displayed analysis. Average confidence combines this model’s majority runs.
LLY is trading in a support retest near $1161-1165 after the Sep 18 FDA full approval of Inluriyo combo for breast cancer, a fresh catalyst that strengthens the oncology pipeline and drove an analyst EPS estimate lift. The stock is bouncing off 4h support with improving momentum (RSI rising, MACD bullish zero-cross) in a calm/bullish macro regime, and prior LLY long setups from support retests have a 3-0 winning record. The expected path is a grind higher toward $1220 as the catalyst reprices and volume normalizes, with the key barrier at $1186.61 resistance that must clear first.
LLY has rallied into 4h upper Bollinger Band extension at $1168.53 following the Sept 18 FDA approval for Inluriyo/Verzenio, but the stock is now sitting directly on 1d support ( $1165.81) with no fresh catalyst to drive further upside. The calm/bullish regime is already priced in, and with volume depressed at the 4th percentile, the post-approval buying exhaustion sets up a mean-reversion short back toward the value area low near $1125 over the next 1-2 weeks. The 4h extension above the upper band combined with fading intraday momentum (30m RSI declining from 65) provides the tactical entry.
Bull/Bear Competition · case scoresWinner: BULL
Case scores describe the displayed analysis. Average confidence combines this model’s majority runs.
Eli Lilly (LLY) is positioned for a bullish swing trade driven by recent FDA approvals for Inluriyo plus Verzenio and Mounjaro, which expand its oncology and diabetes franchises and reinforce its competitive edge in high-growth therapeutic areas. The stock is currently consolidating near high-volume nodes and key support levels, with improving momentum (RSI rising, MACD histogram positive and increasing) and aligned sector confirmation (XLV +0.61%). These catalysts, combined with a calm bullish regime, support a continuation toward prior highs and beyond, with a clear path to $1230-$1250 on a 1-3 week horizon.
LLY presents a compelling short case as it trades at a stretched technical location above its upper Bollinger Band on the 4-hour chart, signaling potential exhaustion in its recent rally. The stock is extended near resistance at $1186.61, with RSI (58.36) showing early signs of losing momentum after a multi-bar rise, suggesting a pullback or reversal is increasingly likely. While the FDA approval of Inluriyo and recent analyst EPS estimate revisions provide a bullish narrative, these catalysts appear priced in, and the stock's failure to sustain momentum above key resistance levels increases the risk of a mean reversion move toward support at $1161.39 or lower.